GlassScriptPhysician profile
Prithvi Mruthyunjaya
NPI 1073670477
$74,236.74
in general payments reported to CMS, 2019-2025
17 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $5,505 · 2021: $8,151 · 2022: $17K · 2023: $23K · 2024: $19K · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Travel and Lodging: $2,591 · Food and Beverage: $1,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,635.00 |
| Travel and Lodging | $2,591.09 |
| Food and Beverage | $1,868.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $54,512.03 | 2020-2025 | Constellation, Unity |
| Dutch Ophthalmic, USA | $5,477.53 | 2022-2023 | Eva, Combined Machine, Tissueblue |
| Amgen INC. | $4,915.00 | 2023 | |
| Genentech USA, INC. | $4,884.35 | 2020-2025 | Susvimo |
| Bausch & Lomb Americas INC. | $1,146.90 | 2022-2024 | Stellaris |
| Immunogen, INC. | $1,126.78 | 2023 | |
| Alcon Research LLC | $700.00 | 2023 | |
| Alimera Sciences, INC. | $356.97 | 2019-2022 | |
| Genentech, INC. | $315.21 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $180.47 | 2024 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $149.37 | 2023 | |
| Immunocore Limited | $125.00 | 2024 | Kimmtrak |
| Carl Zeiss Meditec USA, INC. | $122.70 | 2022 | |
| Eyepoint US, INC. | $111.23 | 2023 | |
| Apellis Pharmaceuticals, INC. | $58.32 | 2025 | Syfovre |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $29.32 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prithvi Mruthyunjaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.